 Glioblastoma
"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 5 | 3 | 8 | | 2007 | 3 | 1 | 4 | | 2008 | 2 | 1 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 6 | 0 | 6 | | 2011 | 2 | 0 | 2 | | 2012 | 9 | 2 | 11 | | 2013 | 11 | 2 | 13 | | 2014 | 11 | 2 | 13 | | 2015 | 15 | 1 | 16 | | 2016 | 13 | 0 | 13 | | 2017 | 14 | 1 | 15 | | 2018 | 17 | 1 | 18 | | 2019 | 12 | 3 | 15 | | 2020 | 14 | 1 | 15 | | 2021 | 14 | 0 | 14 | | 2022 | 15 | 1 | 16 | | 2023 | 17 | 0 | 17 | | 2024 | 9 | 0 | 9 | | 2025 | 14 | 2 | 16 | | 2026 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Lee J, Chung YM, Silver DJ, Hao Y, Harwood DSL, Ealy A, Serapiglia AM, Curtin L, Benedetti JR, Ballard CAP, Lapsley K, Alvarez-Vazquez A, Goldberg J, Li C, Kaur S, Neal R, Wang SZ, Kay KE, Volovetz J, Hong ES, Fodor R, Jarmula J, Nicosia M, Rubin JB, Swanson KR, Ostrom QT, Panicker N, Kristensen BW, Berens M, Sharifi N, Lathia JD. Androgen loss accelerates brain tumour growth via HPA axis activation. Nature. 2026 May; 653(8116):1184-1195.
-
Shen S, Mohan AA, Hotchkiss KM, Cook S, Patel K, Moelker E, Puviindran B, Gonzalez AT, Zaidi S, Spellicy S, Schwartz A, Suryadevara C, Wilkinson D, Ayasoufi K, Fecci PE, Sanchez-Perez L, Sampson J, Patel A. IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma. J Immunother Cancer. 2026 Mar 24; 14(3).
-
Budnik N, Canedo L, Morellato AE, Cuenca MB, Garmendia M, Senin S, Romano SA, Andrysik Z, Videla-Richardson GA, Graner MW, Kobayashi K, Zhou Y, Wiese M, Akhtar A, Espinosa JM, Perez-Castro C. Nucleoli-localized KANSL2 as an epigenetic regulator of ribosome biogenesis in glioblastoma cells. Commun Biol. 2026 Mar 05; 9(1).
-
Wang SZ, Timken JP, Hong ES, Kaur S, Newby E, Kay KE, Mulkearns-Hubert EE, Silver DJ, Lee J, Rubin JB, Connor JR, Deleyrolle LP, Tiek D, Dhawan A, Lathia JD. Lipocalin 2 orchestrates resistance to ferroptosis via AXL. Cell Rep. 2026 Mar 24; 45(3):116965.
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Nelson CB, Wells JK, Kesarwani E, Sobinoff AP, Fernando M, Gao J, MacKenzie KL, Poulos RC, Nawaz U, Wang X, Ford HL, Pickett HA. Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems. Genes Dev. 2026 02 02; 40(3-4):267-283.
-
Ajaib S, Winter-Luke J, Digby RJ, Pollock S, Hemmings G, Gusnanto A, Chakrabarty A, Ismail A, Wilson E, Hunter B, Filby A, McDonald D, Brockman AA, Ihrie RA, Stead LF. Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture, post-treatment. Neuro Oncol. 2025 Dec 01; 27(12):3145-3160.
-
Walton CM, Bell M, O'Neil R, Sahin O, Choi BD, Fecci PE, Strickland BA. Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions. J Immunother Cancer. 2025 Oct 31; 13(10).
-
Zannikou M, Duffy JT, Procissi D, Najem H, Levine RN, Thakur A, Hambardzumyan D, Lee-Chang C, Leoni L, Horbinski CM, Simberg D, Zhang B, Heimberger AB, Miska J, Balyasnikova IV. Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. J Immunother Cancer. 2025 Oct 28; 13(10).
-
Blomquist MR, Noviello TMR, Sereduk C, Grief D, Caruso FP, Sharma R, Garcia-Mansfield K, Pirrotte P, Kloss J, D'Angelo F, Marin BM, Porath K, Jain S, Rabichow B, Ensign SPF, Iavarone A, Paladino A, Sarkaria JN, Loftus JC, Ceccarelli M, Tran NL. Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. J Transl Med. 2025 Oct 21; 23(1):1153.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|